Bevacizumab step therapy for wet AMD may be effective for majority of patients

Patients treated with a step therapy protocol of bevacizumab injections for neovascular age-related macular degeneration experienced similar outcomes as those treated with FDA-approved therapies.
“Based on our findings, bevacizumab step therapy is an effective treatment protocol for exudative age-related macular degeneration, with a long-term treatment success rate of 70.8% of patients, which is comparable to reported success rates of the FDA-approved ranibizumab therapy,” Jonathan Siktberg, a medical student at Vanderbilt University School of Medicine, said at the virtual